Meitheal Pharmaceuticals Strengthens Biologics Portfolio with an Exclusive Commercial Licensing Agreement for YUSIMRY®, a Biosimilar of Humira® [Yahoo! Finance]
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: Yahoo! Finance
YUSIMRY ® is currently approved by the U.S. FDA for nine indications and is available at a lower cost compared to Humira ® ; Meitheal expects additional indications, including a high-concentration formulation, to be approved in 2025 Agreement adds a fifth biosimilar to Meitheal's growing portfolio and supports the Company's commitment to providing sustainable access to critical medicines CHICAGO, June 27, 2024 BUSINESS WIRE )--Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced it has gained exclusive commercial rights in the U.S. to YUSIMRY ® (adalimumab-aqvh), a biosimilar of Humira ® (adalimumab), through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. ("HKF"). "The licensing of YUSIMRY ® is a pivotal moment for Meitheal, solidi
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction [Yahoo! Finance]Yahoo! Finance
- Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash TransactionGlobeNewswire
- Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of DirectorsGlobeNewswire
- Coherus Management to Present at the 2024 Jefferies Global Healthcare ConferenceGlobeNewswire
CHRS
Earnings
- 5/9/24 - Miss
CHRS
Analyst Actions
- 5/24/24 - HC Wainwright
CHRS
Sec Filings
- 6/27/24 - Form 8-K
- 6/5/24 - Form 4
- 6/5/24 - Form 3
- CHRS's page on the SEC website